Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer

Nature Reviews Genetics

Volumn 14, Issue 11, 2013, Pages 765-780

  Plass, Christoph ^a   Pfister, Stefan M ^a,b   Lindroth, Anders M ^a   Bogatyrova, Olga ^a   Claus, Rainer ^c   Lichter, Peter ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; ISOCITRATE DEHYDROGENASE 1; NEUROTROPHIC TYROSINE KINASE RECEPTOR TYPE 1; PROTEIN TYROSINE KINASE; SCATTER FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CANCER CELL; CARCINOGENESIS; CHROMATIN; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENETIC DISORDER; GENOME ANALYSIS; GLIOBLASTOMA; HISTONE MODIFICATION; HUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TUMOR GENE; TUMOR SUPPRESSOR GENE;

CHROMATIN; COMPUTATIONAL BIOLOGY; DNA METHYLATION; EPIGENESIS, GENETIC; GENES, REGULATOR; GENOME; HISTONES; HUMANS; MUTATION; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84886099830     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg3554     Document Type: Review

References (156)

1. Costello, J. F. & Plass, C. Methylation matters. J. Med. Genet. 38, 285-303 (2001). (Pubitemid 32433981)
2. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome - biological and translational implications. Nature Rev. Cancer 11, 726-734 (2011).
3. Esteller, M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21, 5427-5440 (2002). (Pubitemid 34983479)
4. You, J. S. & Jones, P. A. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22, 9-20 (2012).
5. Dawson, M. A. & Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 150, 12-27 (2012).
6. Shen, H. & Laird, P. W. Interplay between the cancer genome and epigenome. Cell 153, 38-55 (2013).
7. Greger, V., Passarge, E., Hopping, W., Messmer, E. & Horsthemke, B. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum. Genet. 83, 155-158 (1989). (Pubitemid 19234564)
8. Baylin, S. B. et al. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res. 46, 2917-2922 (1986). (Pubitemid 16074305)
9. Plass, C. et al. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene 18, 3159-3165 (1999). (Pubitemid 29261237)
10. He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303-1307 (2011).
11. Ito, S. et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300-1303 (2011).
12. Hansen, K. D. et al. Increased methylation variation in epigenetic domains across cancer types. Nature Genet. 43, 768-775 (2011).
13. Gaudet, F. et al. Induction of tumors in mice by genomic hypomethylation. Science 300, 489-492 (2003). (Pubitemid 36444330)
14. Goll, M. G. & Bestor, T. H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 74, 481-514 (2005). (Pubitemid 40995515)
15. Smiraglia, D. J. et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum. Mol. Genet. 10, 1413-1419 (2001). (Pubitemid 32640670)
16. Costello, J. F. et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genet. 24, 132-138 (2000). (Pubitemid 30094712)
17. Brena, R. M. et al. Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung cancer. PLoS Med. 4, e108 (2007).
18. Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425-437 (2012).
19. Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567 (2010).
20. Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681-8686 (1999). (Pubitemid 29354851)
21. Easwaran, H. et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 22, 837-849 (2012).
22. Ohm, J. E. et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature Genet. 39, 237-242 (2007). (Pubitemid 46184356)
23. Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315-326 (2006).
24. Baylin, S. B. & Ohm, J. E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nature Rev. Cancer 6, 107-116 (2006). (Pubitemid 43361543)
25. Xie, W. et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell 153, 1134-1148 (2013).
26. Lister, R. et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462, 315-322 (2009).
27. Schroeder, D. I., Lott, P., Korf, I. & LaSalle, J. M. Large-scale methylation domains mark a functional subset of neuronally expressed genes. Genome Res. 21, 1583-1591 (2011).
28. Hon, G. C. et al. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res. 22, 246-258 (2012).
29. Berman, B. P. et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nature Genet. 44, 40-46 (2012).
30. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539-542 (2011).
31. Korbel, J. O. et al. Paired-end mapping reveals extensive structural variation in the human genome. Science 318, 420-426 (2007). (Pubitemid 47614521)
32. Northcott, P. A. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49-56 (2012).
33. Rausch, T. et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59-71 (2012).
34. Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66-72 (2008).
35. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
36. Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009).
37. Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424-2433 (2010).
38. Letouze, E. et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23, 739-752 (2013).
39. Killian, J. K. et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 3, 648-657 (2013).
40. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
41. Peifer, M. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genet. 44, 1104-1110 (2012).
42. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012).
43. Parsons, D. W. et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435-439 (2011).
44. Jones, D. T. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100-105 (2012).
45. Pugh, T. J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106-110 (2012).
46. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
47. Gonzalez-Perez, A. et al. Computational approaches to identify functional genetic variants in cancer genomes. Nature Methods 10, 723-729 (2013).
48. Okano, M., Bell, D. W., Haber, D. A. & Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247-257 (1999). (Pubitemid 29519904)
49. Li, E., Bestor, T. H. & Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69, 915-926 (1992).
50. Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129-1133 (2010).
51. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935 (2009).
52. Rai, K. et al. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 135, 1201-1212 (2008).
53. Barreto, G. et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 445, 671-675 (2007). (Pubitemid 46232889)
54. Reik, W., Dean, W. & Walter, J. Epigenetic reprogramming in mammalian development. Science 293, 1089-1093 (2001). (Pubitemid 32758081)
55. Yan, X. J. et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genet. 43, 309-315 (2011).
56. Ribeiro, A. F. et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 119, 5824-5831 (2012).
57. Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144-147 (2009).
58. Gaidzik, V. I. et al. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. J. Clin. Oncol. 30, 1350-1357 (2012).
59. Pronier, E. & Delhommeau, F. Role of TET2 mutations in myeloproliferative neoplasms. Curr. Hematol. Malig. Rep. 7, 57-64 (2012).
60. Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474-478 (2012).
61. Andronesi, O. C. et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci. Transl Med. 4, 116ra4 (2012).
62. Elkhaled, A. et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci. Transl Med. 4, 116ra5 (2012).
63. Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012).
64. Elsaesser, S. J., Goldberg, A. D. & Allis, C. D. New functions for an old variant: no substitute for histone H3.3. Curr. Opin. Genet. Dev. 20, 110-117 (2010).
65. Ziemin-van der Poel, S. et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc. Natl Acad. Sci. USA 88, 10735-10739 (1991). (Pubitemid 21915912)
66. Caligiuri, M. A. et al. The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. Proc. Natl Acad. Sci. USA 94, 3899-3902 (1997). (Pubitemid 27180470)
67. Dohner, K. et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J. Clin. Oncol. 20, 3254-3261 (2002). (Pubitemid 34831523)
68. Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nature Rev. Cancer 7, 823-833 (2007). (Pubitemid 350006257)
69. Krivtsov, A. V. et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355-368 (2008).
70. Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178 (2005). (Pubitemid 40546386)
71. Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genet. 42, 665-667 (2010).
72. Visser, H. P. et al. The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112, 950-958 (2001). (Pubitemid 32322920)
73. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003). (Pubitemid 37205983)
74. Varambally, S. et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322, 1695-1699 (2008).
75. Asangani, I. A. et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol. Cell 49, 80-93 (2013).
76. Sneeringer, C. J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980-20985 (2010).
77. Northcott, P. A. et al. Medulloblastomics: the end of the beginning. Nature Rev. Cancer 12, 818-834 (2012).
78. Masica, D. L. & Karchin, R. Collections of simultaneously altered genes as biomarkers of cancer cell drug response. Cancer Res. 73,1699-1708 (2013).
79. Hargreaves, D. C. & Crabtree, G. R. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 21, 396-420 (2011).
80. Clapier, C. R. & Cairns, B. R. The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 78, 273-304 (2009).
81. Shain, A. H. & Pollack, J. R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 8, e55119 (2013).
82. Wilson, B. G. & Roberts, C. W. SWI/SNF nucleosome remodellers and cancer. Nature Rev. Cancer 11, 481-492 (2011).
83. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
84. Cornen, S. et al. Mutations and deletions of ARID1A in breast tumors. Oncogene 31, 4255-4256 (2012).
85. Love, C. et al. The genetic landscape of mutations in Burkitt lymphoma. Nature Genet. 44, 1321-1325 (2012).
86. Sausen, M. et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genet. 45, 12-17 (2013).
87. Wu, J. N. & Roberts, C. W. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 3, 35-43 (2013).
88. Lee, R. S. & Roberts, C. W. Rhabdoid tumors: an initial clue to the role of chromatin remodeling in cancer. Brain Pathol. 23, 200-205 (2013).
89. Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203-206 (1998). (Pubitemid 28325977)
90. Ryan, R. J. & Bernstein, B. E. Molecular biology. Genetic events that shape the cancer epigenome. Science 336, 1513-1514 (2012).
91. Zhang, J. et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nature Genet. 45, 602-612 (2013).
92. Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nature Genet. 44, 251-253 (2012).
93. Venneti, S. et al. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol. 23, 558-564 (2013).
94. Lewis, P. W. et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340, 857-861 (2013).
95. Chan, K. M. et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 27, 985-990 (2013).
96. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199-1203 (2011).
97. Cheung, N. K. et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307, 1062-1071 (2012).
98. Wong, L. H. et al. ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Res. 20, 351-360 (2010).
99. Goldberg, A. D. et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140, 678-691 (2010).
100. Dhayalan, A. et al. The ATRX-ADD domain binds to H3 tail peptides and reads the combined methylation state of K4 and K9. Hum. Mol. Genet. 20, 2195-2203 (2011).
101. Eustermann, S. et al. Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin. Nature Struct. Mol. Biol. 18, 777-782 (2011).
102. Iwase, S. et al. ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome. Nature Struct. Mol. Biol. 18, 769-776 (2011).
103. Heaphy, C. M. et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 333, 425 (2011).
104. Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079-1082 (2002). (Pubitemid 34132239)
105. Liu, S. et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res. 65, 1277-1284 (2005). (Pubitemid 40270154)
106. Hong, C. et al. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. Proc. Natl Acad. Sci. USA 104, 10974-10979 (2007). (Pubitemid 47175211)
107. Zardo, G. et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nature Genet. 32, 453-458 (2002). (Pubitemid 35266125)
108. Smith, L. T. et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc. Natl Acad. Sci. USA 103, 982-987 (2006). (Pubitemid 43212208)
109. Raval, A. et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129, 879-890 (2007). (Pubitemid 46813150)
110. ENCODE Project Consortium et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
111. Weischenfeldt, J. et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 23, 159-170 (2013).
112. Karreth, F. A. et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 147, 382-395 (2011).
113. Lubbert, M. et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J. Clin. Oncol. 29, 1987-1996 (2011).
114. Fenaux, P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nature Clin. Pract. Oncol. 2 (Suppl. 1), 36-44 (2005).
115. Kantarjian, H. M. et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol. 30, 2670-2677 (2012).
116. Claus, R. et al. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leuk. Res. 37, 190-196 (2013).
117. Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626-630 (2013).
118. Ellis, L. et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res. 14, 4500-4510 (2008).
119. Dickinson, M. et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br. J. Haematol. 147, 97-101 (2009).
120. Rathkopf, D. et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 66, 181-189 (2010).
121. Dekker, F. J. & Haisma, H. J. Histone acetyl transferases as emerging drug targets. Drug Discov. Today 14, 942-948 (2009).
122. Avvakumov, N. & Cote, J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 26, 5395-5407 (2007). (Pubitemid 47255922)
123. Furdas, S. D., Kannan, S., Sippl, W. & Jung, M. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch. Pharm. (Weinheim) 345, 7-21 (2012).
124. Liu, X. et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451, 846-850 (2008). (Pubitemid 351253165)
125. McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
126. Schenk, T. et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Med. 18, 605-611 (2012).
127. Chung, C. W. & Witherington, J. Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. J. Biomol. Screen 16, 1170-1185 (2011).
128. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
129. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011).
130. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
131. Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669-16674 (2011).
132. Song, C. X. et al. Genome-wide profiling of 5-formylcytosine reveals its roles in epigenetic priming. Cell 153, 678-691 (2013).
133. Reyon, D. et al. FLASH assembly of TALENs for high-throughput genome editing. Nature Biotech. 30, 460-465 (2012).
134. Kotliarova, S. & Fine, H. A. SnapShot: glioblastoma multiforme. Cancer Cell 21, 710-710.e1 (2012).
135. Bjerke, L. et al. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 3, 512-519 (2013).
136. Schmitges, F. W. et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol. Cell 42, 330-341 (2011).
137. Yuan, W. et al. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J. Biol. Chem. 286, 7983-7989 (2011).
138. Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19, 17-30 (2011).
139. Hirotsune, S. et al. New approach for detection of amplification in cancer DNA using restriction landmark genomic scanning. Cancer Res. 52, 3642-3647 (1992).
140. Huang, T. H., Perry, M. R. & Laux, D. E. Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 8, 459-470 (1999). (Pubitemid 29097334)
141. Sandoval, J. et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6, 692-702 (2011).
142. Gebhard, C. et al. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res. 66, 6118-6128 (2006).
143. Weber, M. et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genet. 37, 853-862 (2005). (Pubitemid 41077111)
144. Meissner, A. et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 33, 5868-5877 (2005). (Pubitemid 41742606)
145. Bibikova, M. et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 16, 383-393 (2006). (Pubitemid 43327509)
146. Adey, A. & Shendure, J. Ultra-low-input, tagmentation-based whole-genome bisulfite sequencing. Genome Res. 22, 1139-1143 (2012).
147. Pastor, W. A., Huang, Y., Henderson, H. R., Agarwal, S. & Rao, A. The GLIB technique for genome-wide mapping of 5-hydroxymethylcytosine. Nature Protoc. 7, 1909-1917 (2012).
148. Yu, M. et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell 149, 1368-1380 (2012).
149. Auerbach, R. K. et al. Mapping accessible chromatin regions using Sono-Seq. Proc. Natl Acad. Sci. USA 106, 14926-14931 (2009).
150. Sajan, S. A. & Hawkins, R. D. Methods for identifying higher-order chromatin structure. Annu. Rev. Genom. Hum. Genet. 13, 59-82 (2012).
151. Roh, T. Y., Ngau, W. C., Cui, K., Landsman, D. & Zhao, K. High-resolution genome-wide mapping of histone modifications. Nature Biotech. 22, 1013-1016 (2004). (Pubitemid 39014479)
152. Barski, A. et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837 (2007). (Pubitemid 46802390)
153. Down, T. A. et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nature Biotech. 26, 779-785 (2008). (Pubitemid 351961453)
154. Laird, P. W. Principles and challenges of genomewide DNA methylation analysis. Nature Rev. Genet. 11, 191-203 (2010).
155. Jin, B. et al. Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells. Cell Rep. 2, 1411-1424 (2012).
156. Adli, M. & Bernstein, B. E. Whole-genome chromatin profiling from limited numbers of cells using nano-ChIP-seq. Nature Protoc. 6, 1656-1668 (2011).